The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Abstract
BACKGROUND: Concerns regarding the safety of transfused blood have led to the development of a range of interventions to minimise blood loss during major surgery. Anti-fibrinolytic drugs are widely used, particularly in cardiac surgery and previous reviews have found them to be effective in reducing blood loss and the need for transfusion. Recently, questions have been raised regarding the comparative performance of the drugs and the safety of the most popular agent, aprotinin. OBJECTIVES: To assess the comparative effects of the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon aminocaproic acid (EACA) on blood loss during surgery, the need for red blood (RBC) transfusion, and adverse events, particularly vascular occlusion, renal dysfunction, and death. SEARCH STRATEGY: We searched CENTRAL, MEDLINE, EMBASE, and the internet. References in identified trials and review articles were checked and trial authors were contacted to identify any additional studies. The searches were last updated in July 2006. SELECTION CRITERIA: Randomised controlled trials (RCTs) of anti-fibrinolytic drugs in adults scheduled for non-urgent surgery. Eligible trials compared anti-fibrinolytic drugs with placebo (or no treatment), or with each other. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. MAIN RESULTS: This review summarises data from 211 RCTs that recruited 20,781 participants. Data from placebo/inactive controlled trials, and from head-to-head trials suggest an advantage of aprotinin over the lysine analogues TXA and EACA in terms of operative blood loss, but the differences were small. Aprotinin reduced the probability of requiring RBC transfusion by a relative 34% (relative risk [RR] 0.66, 95% confidence interval [CI] 0.61 to 0.71). The RR for RBC transfusion with TXA was 0.61 (95% CI 0.54 to 0.69) and it was 0.75 (95% CI 0.58 to 0.96) with EACA. When the pooled estimates from the head-to-head trials of the two lysine analogues were combined and compared to aprotinin alone, aprotinin appeared superior in reducing the need for RBC transfusion: RR 0.83 (95% CI 0.69 to 0.99). Aprotinin reduced the need for re-operation due to bleeding: RR 0.48 (95% CI 0.35 to 0.68). This translates into an absolute risk reduction of just under 3% and a number needed-to-treat (NNT) of 37 (95% CI 27 to 56). Similar trends were seen with TXA and EACA, but the data were sparse and the differences failed to reach statistical significance. The blood transfusion data were heterogeneous and funnel plots indicate that trials of aprotinin and the lysine analogues may be subject to publication bias. Evidence of publication bias was not observed in trials reporting re-operation rates. Adjustment for these effects reduced the magnitude of estimated benefits but did not negate treatment effects. However, the apparent advantage of aprotinin over the lysine analogues was small and may be explained by publication bias and non-equivalent drug doses. Aprotinin did not increase the risk of myocardial infarction (RR 0.92, 95% CI 0.72 to 1.18), stroke (RR 0.76, 95% CI 0.35 to 1.64) renal dysfunction (RR 1.16, 95% CI 0.79 to 1.70) or overall mortality (RR 0.90, 95% CI 0.67 to 1.20). The analyses of myocardial infarction and death included data from the majority of subjects recruited into the clinical trials of aprotinin. However, under-reporting of renal events could explain the lack of effect seen with aprotinin. Similar trends were seen with the lysine analogues but data were sparse. These results conflict with the results of recently published non-randomised studies. AUTHORS' CONCLUSIONS: Anti-fibrinolytic drugs provide worthwhile reductions in blood loss and the need for allogeneic red cell transfusion. Based on the results of randomised trials their efficacy does not appear to be offset by serious adverse effects. In most circumstances the lysine analogues are probably as effective as aprotinin and are cheaper; the evidence is stronger for tranexamic acid than for aminocaproic acid. In high risk cardiac surgery, where there is a substantial probability of serious blood loss, aprotinin may be preferred over tranexamic acid. Aprotinin does not appear to be associated with an increased risk of vascular occlusion and death, but the data do not exclude an increased risk of renal failure. There is no need for further placebo-controlled trials of aprotinin or lysine analogues in cardiac surgery. The principal need is for large comparative trials to assess the relative efficacy, safety and cost-effectiveness of anti-fibrinolytic drugs in different surgical procedures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
Hébert, P. C., Wells, G., Blajchman, M. A., Marshall, J., Martin, C., Pagliarello, G., Tweeddale, M., Schweitzer, I., & Yetisir, E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400601 · Cited by 5,187
The Risk Associated with Aprotinin in Cardiac Surgery
Mangano, D. T., Tudor, I. C., & Dietzel, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051379 · Cited by 1,099
EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY
Royston, D., Taylor, K. M., Bidstrup, B. P., & Sapsford, R. N. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91190-1 · Cited by 677
Mannucci, P. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390407 · Cited by 557
Levi, M., Cromheecke, M. E., de Jonge, E., Prins, M. H., de Mol, B. J., Briët, E., & Büller, H. R. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01264-7 · Cited by 545
Bidstrup, B. P., Royston, D., Sapsford, R. N., Taylor, K. M., & Cosgrove, D. M. (1989) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)34573-8 · Cited by 526
The independent association of massive blood loss with mortality in cardiac surgery
Karkouti, K., Wijeysundera, D. N., Yau, T. M., Beattie, W. S., Abdelnaem, E., McCluskey, S. A., Ghannam, M., Yeo, E., Djaiani, G., & Karski, J. (2004) · Transfusion · doi:10.1111/j.1537-2995.2004.04144.x · Cited by 452
Cited by
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Henry, D. A., Carless, P. A., Moxey, A. J., O’Connell, D. L., Stokes, B., Fergusson, D. A., & Ker, K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001886.pub4 · Cited by 1,065
Self-citationRoberts, I., Shakur, H., Coats, T., Hunt, B., Balogun, E., Barnetson, L., Cook, L., Kawahara, T., Perel, P., Prieto-Merino, D., et al. (2013) · Health Technol Assess · doi:10.3310/hta17100 · Cited by 794
Bowen, T., Cicardi, M., Farkas, H., Bork, K., Longhurst, H. J., Zuraw, B., Aygoeren-Pürsün, E., Craig, T., Binkley, K., Hebert, J., et al. (2010) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-6-24 · Cited by 614
Cell salvage for minimising perioperative allogeneic blood transfusion
Carless, P. A., Henry, D. A., Moxey, A. J., O’Connell, D. L., Brown, T. J., & Fergusson, D. A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001888.pub4 · Cited by 462
Self-citationAnti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Henry, D. A., Carless, P. A., Moxey, A. J., O'Connell, D., Stokes, B. J., Fergusson, D. A., & Ker, K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001886.pub3 · Cited by 398
Self-citationGiglia, T. M., Massicotte, M. P., Tweddell, J. S., Barst, R. J., Bauman, M., Erickson, C. C., Feltes, T. F., Foster, E., Hinoki, K., Ichord, R. N., et al. (2013) · Circulation · doi:10.1161/01.cir.0000436140.77832.7a · Cited by 390
Shakur, H., Elbourne, D., Gülmezoglu, M., Alfirevic, Z., Ronsmans, C., Allen, E., & Roberts, I. (2010) · Trials · doi:10.1186/1745-6215-11-40 · Cited by 332
Alshryda, S., Sukeik, M., Sarda, P., Blenkinsopp, J., Haddad, F. S., & Mason, J. M. (2014) · The Bone & Joint Journal · doi:10.1302/0301-620x.96b8.33745 · Cited by 321
Antifibrinolytic drugs for acute traumatic injury
Ker, K., Roberts, I., Shakur, H., & Coats, T. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004896.pub4 · Cited by 320
Tranexamic acid–associated seizures: Causes and treatment
Lecker, I., Wang, D., Whissell, P. D., Avramescu, S., Mazer, C. D., & Orser, B. A. (2016) · Annals of Neurology · doi:10.1002/ana.24558 · Cited by 282
Antifibrinolytic agents in current anaesthetic practice
Ortmann, E., Besser, M. W., & Klein, A. A. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet154 · Cited by 262
Efficacy of tranexamic acid on surgical bleeding in spine surgery: a meta-analysis
Cheriyan, T., Maier, S. P., Bianco, K., Slobodyanyuk, K., Rattenni, R. N., Lafage, V., Schwab, F. J., Lonner, B. S., & Errico, T. J. (2015) · The Spine Journal · doi:10.1016/j.spinee.2015.01.013 · Cited by 259
KEELING, D., TAIT, C., & MAKRIS, M. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01695.x · Cited by 258
Thrombelastography and tromboelastometry in assessing coagulopathy in trauma
Johansson, P. I., Stissing, T., Bochsen, L., & Ostrowski, S. R. (2009) · Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine · doi:10.1186/1757-7241-17-45 · Cited by 255
Role of fibrinogen in trauma-induced coagulopathy
Fries, D., & Martini, W. Z. (2010) · British Journal of Anaesthesia · doi:10.1093/bja/aeq161 · Cited by 254
Metadata
- Authors
- Henry, D. A., Carless, P. A., Moxey, A. J., O'Connell, D., Stokes, B. J., McClelland, B., Laupacis, A., & Fergusson, D. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2007-10-17
- Issue
- 4
- Pages
- CD001886-CD001886
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4238817203
- Cited by
- 256
- References
- 58
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.